Sudocetaxel zendusortide - Theratechnologies
Alternative Names: DoceKA; Docetaxel-KA-peptide conjugate; Sudocetaxel Zendusortide; TH-1902Latest Information Update: 12 Dec 2024
At a glance
- Originator Katana Biopharma
- Developer Theratechnologies
- Class Antineoplastics; Drug conjugates; Peptide drug conjugates; Peptides; Small molecules; Taxanes
- Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Triple negative breast cancer
Most Recent Events
- 09 Dec 2024 Updated efficacy and adverse event data from a phase I trial in Solid tumours released by Theratechnologies
- 31 May 2024 Efficacy and adverse event data from a phase I trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 24 May 2024 Efficacy and pharmacokinetics data from a phase I trial in Solid tumours released by Theratechnologies